212.09 -1.69 (-0.79%)
After hours: 4:11PM EST
|Bid||210.00 x 900|
|Ask||214.64 x 800|
|Day's range||208.82 - 214.40|
|52-week range||105.05 - 214.40|
|Beta (3Y monthly)||0.63|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||206.31|
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
Today we will run through one way of estimating the intrinsic value of DexCom, Inc. (NASDAQ:DXCM) by estimating the...
DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.